Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.

Blazevski A, Scheltema MJ, Amin A, Thompson JE, Lawrentschuk N, Stricker PD.

BJU Int. 2019 Nov 14. doi: 10.1111/bju.14951. [Epub ahead of print] Review.

PMID:
31725935
2.

Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.

Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.

BJU Int. 2019 Nov 4. doi: 10.1111/bju.14944. [Epub ahead of print] Review.

PMID:
31680398
3.

Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men.

Feng Y, Jaratlerdsiri W, Patrick SM, Lyons RJ, Haynes AM, Collins CC, Stricker PD, Bornman MSR, Hayes VM.

Prostate. 2019 Nov;79(15):1731-1738. doi: 10.1002/pros.23897. Epub 2019 Aug 27.

4.

p53 nuclear accumulation as an early indicator of lethal prostate cancer.

Quinn DI, Stricker PD, Kench JG, Grogan J, Haynes AM, Henshall SM, Grygiel JJ, Delprado W, Turner JJ, Horvath LG, Mahon KL.

Br J Cancer. 2019 Oct;121(7):578-583. doi: 10.1038/s41416-019-0549-8. Epub 2019 Aug 14.

PMID:
31409910
5.

Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.

Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L.

BJU Int. 2019 Nov;124 Suppl 1:42-49. doi: 10.1111/bju.14794. Epub 2019 Jul 9.

6.

Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences.

Scheltema MJ, O'Brien TJ, van den Bos W, de Bruin DM, Davalos RV, van den Geld CWM, Laguna MP, Neal RE 2nd, Varkarakis IM, Skolarikos A, Stricker PD, de Reijke TM, Arena CB, de la Rosette J.

Ther Adv Urol. 2019 Jun 7;11:1756287219852305. doi: 10.1177/1756287219852305. eCollection 2019 Jan-Dec.

7.

Editorial Comment.

Stricker PD, Van Leeuwen PJ.

J Urol. 2019 Jun;201(6):1142. doi: 10.1097/01.JU.0000554684.52942.bc. No abstract available.

PMID:
30870068
8.

Editorial Comment.

Thompson JE, Stricker PD.

J Urol. 2019 Feb;201(2):306-307. doi: 10.1097/01.JU.0000553007.26960.b9. No abstract available.

PMID:
30634362
9.

Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50.

Gielchinsky I, Scheltema MJ, Cusick T, Chang J, Shnier R, Moses D, Delprado W, Nguyen Q, Yuen C, Haynes AM, Stricker PD.

Res Rep Urol. 2018 Oct 4;10:145-150. doi: 10.2147/RRU.S169017. eCollection 2018.

10.

Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.

Gielchinsky I, Chang J, Cusick T, Delprado W, Nguyen Q, Yuen C, Savdie R, Böhm M, Haynes AM, Scheltema MJ, Stricker PD.

BJU Int. 2018 Nov;122 Suppl 5:35-41. doi: 10.1111/bju.14586. Epub 2018 Nov 8.

11.

Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer.

Jaratlerdsiri W, Chan EKF, Gong T, Petersen DC, Kalsbeek AMF, Venter PA, Stricker PD, Bornman MSR, Hayes VM.

Cancer Res. 2018 Dec 15;78(24):6736-6746. doi: 10.1158/0008-5472.CAN-18-0254. Epub 2018 Sep 14.

PMID:
30217929
12.

Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments.

Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV, Reijke TM, Siriwardana AR, Böhm M, de la Rosette JJ, Stricker PD.

Diagn Interv Radiol. 2018 Sep;24(5):268-275. doi: 10.5152/dir.2018.17374.

13.

Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings.

Penzias G, Singanamalli A, Elliott R, Gollamudi J, Shih N, Feldman M, Stricker PD, Delprado W, Tiwari S, Böhm M, Haynes AM, Ponsky L, Fu P, Tiwari P, Viswanath S, Madabhushi A.

PLoS One. 2018 Aug 31;13(8):e0200730. doi: 10.1371/journal.pone.0200730. eCollection 2018.

14.

MRI improves active surveillance of prostate cancer however biopsy is still crucial.

Thompson JE, Stricker PD.

BJU Int. 2018 Aug;122(2):E1-E2. doi: 10.1111/bju.14424. No abstract available.

15.

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, Chenevix-Trench G, Toso M, Kench JG, Horvath LG, Hayes VM, Stricker PD, Hughes TP, White DL, Rasko JEJ, Wong JJ, Clark SJ.

Epigenetics Chromatin. 2018 May 28;11(1):24. doi: 10.1186/s13072-018-0194-0.

16.

Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.

Scheltema MJ, Chang JI, Böhm M, van den Bos W, Blazevski A, Gielchinsky I, Kalsbeek AMF, van Leeuwen PJ, Nguyen TV, de Reijke TM, Siriwardana AR, Thompson JE, de la Rosette JJ, Stricker PD.

World J Urol. 2018 Sep;36(9):1383-1389. doi: 10.1007/s00345-018-2281-z. Epub 2018 Mar 28.

17.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ.

Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.

PMID:
29314097
18.

Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases.

Thompson JE, Egger S, Böhm M, Siriwardana AR, Haynes AM, Matthews J, Scheltema MJ, Stricker PD.

Eur Urol. 2018 May;73(5):664-671. doi: 10.1016/j.eururo.2017.11.035. Epub 2017 Dec 19.

PMID:
29273404
19.

Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.

Kalsbeek AMF, Chan EKF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Prostate. 2018 Jan;78(1):25-31. doi: 10.1002/pros.23440. Epub 2017 Nov 14.

PMID:
29134670
20.

Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.

Scheltema MJ, Chang JI, van den Bos W, Böhm M, Delprado W, Gielchinsky I, de Reijke TM, de la Rosette JJ, Siriwardana AR, Shnier R, Stricker PD.

Eur Urol Focus. 2019 Jul;5(4):585-591. doi: 10.1016/j.euf.2017.10.007.

PMID:
29102671
21.

Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.

Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.

BJU Int. 2017 Nov;120 Suppl 3:51-58. doi: 10.1111/bju.13991. Epub 2017 Sep 19.

22.

Focal irreversible electroporation as primary treatment for localized prostate cancer.

van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.

BJU Int. 2018 May;121(5):716-724. doi: 10.1111/bju.13983. Epub 2017 Sep 4.

23.

The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.

Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.

J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23.

24.

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.

Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG, Horvath LG.

Ann Oncol. 2017 Aug 1;28(8):1903-1909. doi: 10.1093/annonc/mdx247.

PMID:
28486686
25.

Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.

Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W, Turner J, Horvath LG, Kench JG.

BJU Int. 2017 Nov;120(5):651-658. doi: 10.1111/bju.13857. Epub 2017 Apr 30.

26.

A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.

van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, Abuodha M, Haynes AM, Ting F, Barentsz J, Roobol M, Vass J, Rasiah K, Delprado W, Stricker PD.

BJU Int. 2017 Dec;120(6):774-781. doi: 10.1111/bju.13814. Epub 2017 Mar 31.

27.

Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer.

Thompson JE, Stricker PD.

Lancet. 2017 Feb 25;389(10071):767-768. doi: 10.1016/S0140-6736(17)30121-6. Epub 2017 Jan 23. No abstract available.

28.

Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.

Bruce HM, Stricker PD, Gupta R, Savdie RR, Haynes AM, Mahon KL, Lin HM, Kench JG, Horvath LG.

Prostate. 2016 Dec;76(16):1491-1500. doi: 10.1002/pros.23233. Epub 2016 Jul 30.

PMID:
27473574
29.

Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.

Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Aging (Albany NY). 2016 Oct 5;8(11):2702-2712. doi: 10.18632/aging.101044.

30.

AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments.

Penzias G, Janowczyk A, Singanamalli A, Rusu M, Shih N, Feldman M, Stricker PD, Delprado W, Tiwari S, Böhm M, Haynes AM, Ponsky L, Viswanath S, Madabhushi A.

Sci Rep. 2016 Jul 26;6:29906. doi: 10.1038/srep29906.

31.
32.

Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.

BJU Int. 2017 Feb;119(2):209-215. doi: 10.1111/bju.13540. Epub 2016 Jun 18.

33.

Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide.

Ting F, Van Leeuwen PJ, Stricker PD.

J Vasc Interv Radiol. 2016 Apr;27(4):568. doi: 10.1016/j.jvir.2016.01.003.

PMID:
27013005
34.

The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer.

Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2016 May;195(5):1428-1435. doi: 10.1016/j.juro.2015.10.140. Epub 2015 Oct 31.

PMID:
26529298
35.

Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.

Ting F, Tran M, Böhm M, Siriwardana A, Van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, Stricker PD.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):46-52. doi: 10.1038/pcan.2015.47. Epub 2015 Oct 13.

PMID:
26458959
36.

Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.

Ting F, van Leeuwen PJ, Delprado W, Haynes AM, Brenner P, Stricker PD.

Prostate. 2015 Nov;75(15):1768-73. doi: 10.1002/pros.23062. Epub 2015 Aug 18.

PMID:
26282713
37.

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.

J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.

38.

Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy.

Tran M, Thompson J, Böhm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker PD.

BJU Int. 2016 Jan;117(1):48-54. doi: 10.1111/bju.13090. Epub 2015 May 11.

39.

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C, Emberton M.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):343-7. doi: 10.1038/pcan.2014.33. Epub 2014 Sep 2.

40.

Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?

Gupta R, O'Connell R, Haynes AM, Stricker PD, Barrett W, Turner JJ, Delprado W, Horvath LG, Kench JG.

BJU Int. 2015 Sep;116(3):343-50. doi: 10.1111/bju.12911. Epub 2014 Dec 15.

41.

Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer.

Thompson JE, Hayen A, Landau A, Haynes AM, Kalapara A, Ischia J, Matthews J, Frydenberg M, Stricker PD.

BJU Int. 2015 Jun;115(6):884-91. doi: 10.1111/bju.12858. Epub 2014 Oct 23.

43.

Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2014 Jul;192(1):67-74. doi: 10.1016/j.juro.2014.01.014. Epub 2014 Feb 8.

PMID:
24518762
44.

A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients.

Sooriakumaran P, Srivastava A, Shariat SF, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Mottrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado WJ, Haynes AM, Steyerberg E, Roobol MJ, Tewari AK.

Eur Urol. 2014 Sep;66(3):450-6. doi: 10.1016/j.eururo.2013.11.018. Epub 2013 Nov 24.

PMID:
24290695
45.

Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases.

Thompson JE, Egger S, Böhm M, Haynes AM, Matthews J, Rasiah K, Stricker PD.

Eur Urol. 2014 Mar;65(3):521-31. doi: 10.1016/j.eururo.2013.10.030. Epub 2013 Oct 31.

PMID:
24287319
46.

Circulating microRNAs predict biochemical recurrence in prostate cancer patients.

Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD.

Br J Cancer. 2013 Aug 6;109(3):641-50. doi: 10.1038/bjc.2013.369. Epub 2013 Jul 11.

47.

A novel method of bladder neck imbrication to improve early urinary continence following robotic-assisted radical prostatectomy.

Beattie K, Symons J, Chopra S, Yuen C, Savdie R, Thanigasalam R, Haynes AM, Matthews J, Brenner PC, Rasiah K, Sutherland RL, Stricker PD.

J Robot Surg. 2013 Jun;7(2):193-9. doi: 10.1007/s11701-012-0371-2. Epub 2012 Jul 26.

PMID:
27000912
48.

Outcomes of transperineal template-guided prostate biopsy in 409 patients.

Symons JL, Huo A, Yuen CL, Haynes AM, Matthews J, Sutherland RL, Brenner P, Stricker PD.

BJU Int. 2013 Sep;112(5):585-93. doi: 10.1111/j.1464-410X.2012.11657.x. Epub 2013 Apr 3.

49.

High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse.

Savdie R, Symons J, Spernat D, Yuen C, Pe Benito RA, Haynes AM, Matthews J, Rasiah KK, Jagavkar RS, Yu C, Fogarty G, Kattan MW, Brenner P, Sutherland RL, Stricker PD.

BJU Int. 2012 Dec;110 Suppl 4:71-6. doi: 10.1111/j.1464-410X.2012.11480.x.

50.

Informed prostate cancer risk-adjusted testing: a new paradigm.

Stricker PD, Frydenberg M, Kneebone A, Chopra S.

BJU Int. 2012 Dec;110 Suppl 4:30-4. doi: 10.1111/j.1464-410X.2012.11621.x. Review.

Supplemental Content

Loading ...
Support Center